Open AccessPerformance of anti‐Müllerian hormone (AMH) levels measured by Beckman Coulter Access AMH assay to predict oocyte yield following controlled ovarian stimulation for in vitro fertilization
Author(s) -
Asada Yoshimasa,
Tsuiki Miyako,
Sonohara Megumi,
Fukunaga Noritaka,
Hattori Yukio,
Inoue Daichi,
Ito Rie,
Hashiba Yoshiki
Publication year - 2019
Publication title -
reproductive medicine and biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.005
H-Index - 22
eISSN - 1447-0578
pISSN - 1445-5781
DOI - 10.1002/rmb2.12271
Subject(s) - anti müllerian hormone , in vitro fertilisation , oocyte , ovarian reserve , andrology , follicle stimulating hormone , stimulation , medicine , human fertilization , ovarian follicle , hormone , endocrinology , biology , embryo , luteinizing hormone , pregnancy , infertility , anatomy , microbiology and biotechnology , genetics
Abstract Purpose We evaluated the performance of anti‐Müllerian hormone (AMH) measured by the Beckman Coulter fully automated Access assay to predict oocyte yield following controlled ovarian stimulation (COS) for in vitro fertilization (IVF). Methods The correlation between the Access assay and the pre‐mixing method with Generation II ELISA assay (Gen II pre‐mix assay) was assessed using 230 blood samples. The relationship of AMH level measured by the Access assay and the actual number of oocytes retrieved following COS was assessed using 3296 IVF cycles. The performances of AMH, follicle stimulating hormone (FSH), and estradiol (E2) in predicting the responses to COS were also evaluated by constructing receiver operating characteristic (ROC) curves. Results The AMH levels measured just before oocyte retrieval by the Access assay and the number of oocytes retrieved following COS showed a good correlation with R = 0.655. The ROC analysis revealed that the sensitivity of AMH was comparable with or lower than that of E2 but higher than that of FSH. Conclusions With the improved Access AMH assays, AMH was as sensitive as E2 and could become an accurate marker of ovarian response to COS in more than 3000 Japanese IVF patients.